ALLMedicine™ Amyopathic Dermatomyositis Center

Jun 18th, 2022 - Amyopathic dermatomyositis (ADM) is a heterogeneous and life-threatening autoimmune disease with high mortality. In particular, anti-MDA5 antibody-positive patients are at high risk of developing rapidly progressive interstitial lung disease (ILD)...

Apr 26th, 2022 - This study aimed to evaluate whether the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) could appropri...

Apr 12th, 2022 - Among the myositis-specific antibodies (MSA), anti-transcriptional intermediary factor 1 (TIF1)-γ and anti-nuclear matrix protein 2 (NXP2) antibodies are reportedly associated with cancer-associated myositis (CAM). We aimed to investigate patient ...

Mar 22nd, 2022 - Deficiency for AIRE/Aire in both humans and mice results in the development of organ-specific autoimmune disease. We tested whether augmented and/or dysregulated AIRE/Aire expression might be also prone to the breakdown of self-tolerance. To defin...

Feb 25th, 2022 - To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. We conducted a multicentre, international, retrospective cohort study. 149 anti-MDA5 positive patients (median onset age 53 years, m...

Sep 16th, 2021 - Adult and juvenile dermatomyositis (DM) are systemic immune-mediated inflammatory diseases most commonly affecting the skin and musculoskeletal system. Amyopathic dermatomyositis is a subtype of dermatomyositis that affects only the skin and lacks...

Jul 19th, 2021 - Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by chronic inflammation in the skin and muscle. Anti-melanoma differentiation-associated gene5 (Anti-MDA5) antibody positive DM is a subtype of DM that is more frequent in E...

Nov 3rd, 2020 - Acute respiratory distress syndrome (ARDS) occurs in Clinically Amyopathic Dermatomyisitis(CADM) combined with Rapidly Progressive Interstitial Lung Disease(RPILD) within 1-3 months, which leads to death of patients and is difficult to treat. Even...

Jun 20th, 2017 - This is a 52-week, randomized, open and routine treatment controlled study. This study will assess the safety and efficacy of basiliximab as an add-on treatment for interstitial pneumonia in clinical amyopathic dermatomyositis (CADM) patients. 100...

Jul 1st, 2016 - Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) with prevalence up to 65%, and is considered to be one of the determining factors of prognosis. Clinical amyopathic dermatomyositis (CADM), which is a special phenoty...

Nov 24th, 2021 - Clinical assessment for pulmonary disease and malignancy in patients with dermatomyositis should not be replaced with serologic tests at this time, according to Jeffrey P. Callen, MD.

Apr 8th, 2019 - The Diagnosis: Juvenile Dermatomyositis Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy of childhood that is autoimmune in nature with an annual incidence ranging from 2. 5 to 4.

Apr 8th, 2019 - The Diagnosis: Juvenile Dermatomyositis Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy of childhood that is autoimmune in nature with an annual incidence ranging from 2. 5 to 4.

Jun 3rd, 2018 - “We saw that there was a much higher rate of misdiagnosis in patients who didn’t have any muscle disease. We have to raise awareness that amyopathic dermatomyositis is a very prevalent condition,” Dr.

Jun 3rd, 2018 - ORLANDO – There was a median 1-year delay between the onset of symptoms and diagnosis of classic dermatomyositis, and a 17-month delay before diagnosis of amyopathic dermatomyositis, based on a review of 232 dermatomyositis patients seen at the Un.